An observational study in Cardiometabolic Diseases, sponsored by Weill Cornell Medical College in Qatar. Not yet recruiting at 1 site in Qatar. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Weill Cornell Medical College in Qatar · Observational
Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.
Qatar, along with other Gulf Cooperation Council (GCC) countries, experiences one of the highest rates of diabetes, obesity, and cardiovascular risk factors. However, the impact of those risk factors on cardiac diseases, in particular atherosclerotic cardiovascular disease (ASCVD), is not well studied. Further, the incidence of mortality in participants with diabetes and high cardiovascular risk is not known.
We will conduct a prospective, longitudinal, observational cohort that investigates the natural history of cardiometabolic diseases in citizens and long-term residents in Qatar: the Qatar Cardiometabolic Cohort (QCMC). The cohort will examine the prevalence, risk factors, and characterization of cardiometabolic patients, as well as the incidence of mortality and ASCVD events.
1,517 studies on the registry are indexed under Atherosclerosis; 224 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 250 across 527 observational studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Weill Cornell Medical College in Qatar is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Participants will be recruited at Hamad Medical Corporation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.
ASCVD:
ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.
i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:
Coronary Artery Disease (CAD)
Cerebrovascular Disease
•Ischemic stroke or (TIA)
Peripheral Arterial Disease (PAD) •Intermittent claudication with objective evidence of arterial obstruction
•Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI \<0.9
a. Coronary artery calcium (CAC) score >100 Agatston units or >75th percentile for age and sex b. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery c. Carotid ultrasound or angiography showing plaque or ≥50% stenosis d. Lower-limb CT/MR/Doppler angiography showing atherosclerotic plaque or stenosis ≥50%
Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines): •10-year fatal/non-fatal CVD risk ≥7.5% using SCORE2 (ages 40-49),≥10% using SCORE2 (ages 50-69), or ≥15% using SCORE2-OP (age≥70 years)
•Severe chronic kidney disease (CKD) with estimated (eGFR) \<30 mL/min/1.73m²; or eGFR 30-44 mL/min/1.73 m² and UACR >30 mg/g.
ii.In diabetic patients (ESC 2023 Diabetes \& CVD Guidelines):
•10-year fatal/non-fatal CVD risk ≥20% using SCORE2-Diabetes (ages 40-69),or ≥15% using SCORE2-OP (age ≥70),since SCORE2-Diabetes is not validated beyond age 69. Severe target organ damage:
•Severe target organ damage:
<!-- -->
3.Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-diabetic patients, defined as having an HbA1c \< 5.7%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk
Patients with pre-diabetes, defined as having an HbA1c between 5.7≤HbA1C ≤6.4, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk
Patients with type 2 diabetes, defined as having an HbA1c ≥ 6.5%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.
Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes)
To compare the incidence of major adverse cardiovascular events (3-point MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) across three groups of adults with established ASCVD or very high cardiovascular risk: non-diabetes, pre-diabetes, and type 2 diabetes.
Time frame: Baseline, Year 2, and Year 5
Change in body mass index (BMI)
Change in BMI (kg/m²) from baseline (Year 0) to Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5
Change in waist-to-hip ratio
Change in waist-to-hip ratio from baseline (Year 0) at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5
Change in fasting glucose
Change in fasting glucose from baseline (Year 0) at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5.
Change in glycated hemoglobin (HbA1c)
Change in HbA1c (%) from baseline (Year 0) at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5
Change in lipid profile parameters
Parameters include total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Changes from baseline will be assessed at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5.
Change in systolic and diastolic blood pressure
Change in systolic and diastolic blood pressure (mmHg) from baseline (Year 0) at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5
Electrocardiogram (ECG) - Heart Rate
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline in heart rate -beats per minute will be assessed at Year 2 and Year 5."
Time frame: Baseline, Year 2, and Year 5.
ECG - PR interval
ECGs will be evaluated for clinically significant abnormalities. Changes from baseline will be assessed in the PR interval (ms-milli second) at Year 2 and Year 5."
Time frame: Baseline, Year 2, and Year 5.
ECG - QTc interval
ECGs will be evaluated for clinically significant abnormalities in the QTc interval in ms-milliseconds. Changes from baseline will be assessed at Year 2 and Year 5."
Time frame: Baseline, Year 2, and Year 5
ECG- QRS Duration
ECGs will be evaluated for clinically significant abnormalities in the QRS duration (ms-milli second). Changes from baseline will be assessed at Year 2 and Year 5.
Time frame: Baseline, Year 2, and Year 5.
Liver Stiffness Measurement
Change in liver stiffness (kPa) assessed by Fibroscan from baseline (Year 0) at Year 2 and Year 5
Time frame: Baseline, Year 2, and Year 5
Controlled Attenuation Parameter
Quantitative measure obtained by FibroScan (transient elastography) that assesses hepatic steatosis (liver fat content)- Unit: decibels per meter (dB/m) by measuring ultrasound attenuation in the liver.
Time frame: Baseline, Year 2, and Year 5
Left Ventricular Ejection Fraction - LVEF
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular ejection fraction (LVEF, %).
Time frame: Baseline, Year 2, and Year 5.
Left Ventricular Mass Index
Transthoracic echocardiography will be performed using standard imaging protocols. Parameters assessed will include left ventricular mass index unit- (g/m²).
Time frame: Baseline, Year 2, and Year 5.
E/e' Ratio
Ratio of mitral inflow velocity to mitral annular tissue velocity; estimates left ventricular filling pressures and diastolic dysfunction severity assessed by Transthoracic echocardiography.
Time frame: Baseline, Year 2, and Year 5.
E/A Ratio
Ratio of early (E) to late (A) mitral inflow velocities; used to assess left ventricular diastolic filling pattern to be assessed by Transthoracic echocardiography.
Time frame: Baseline, Year 2, and Year 5.
Pulmonary Artery Systolic Pressure - PASP
Estimated pressure in the pulmonary artery derived from tricuspid regurgitation velocity; reflects pulmonary hypertension and right heart load will be measured using Transthoracic echocardiography in mmHg.
Time frame: Baseline, Year 2, and Year 5.
Tricuspid Annular Plane Systolic Excursion - TAPSE
Measure longitudinal movement of the tricuspid annulus, indicator of right ventricular systolic function in Transthoracic echocardiography unit mm.
Time frame: Baseline, Year 2, and Year 5.
Incidence of major adverse cardiovascular events (4-point MACE)
4-point MACE will be defined as a composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, and hospitalization for unstable angina
Time frame: Baseline (Year 0), Year 2, and Year 5
Incidence of new-onset cardiac diseases and cardiovascular revascularization procedures
New-onset cardiac diseases will include heart failure, atrial fibrillation or other arrhythmias, and valvular heart disease. Cardiovascular revascularization procedures will include coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI/PTCA), carotid angioplasty, carotid endarterectomy, and lower limb revascularization.
Time frame: Baseline (Year 0), Year 2, Year 5
Incidence of new non-cardiac diseases requiring hospitalization
This outcome includes the development of any new non-cardiac medical condition requiring hospital admission, excluding cardiovascular causes. Hospitalizations will be categorized by system (e.g., infectious, respiratory, renal, gastrointestinal, or other medical causes).
Time frame: Baseline (Year 0), Year 2, and Year 5
Plan to share: Undecided — ongoing discussion with the sponsor
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2036, 120 months later.
Of 144 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 120 months is above that.
Counting every sponsor, half of 169 studies reached it within 62 months; a quarter within 31 and three quarters within 153.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jun 2026 → Dec 2026, primary completion Jun 2036 → Dec 2036 and completion Jun 2036 → Dec 2036.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Cornell Medical College in Qatar